India · Delayed Price · Currency is INR Aarti Drugs Statistics
Total Valuation
Aarti Drugs has a market cap or net worth of INR 45.66 billion. The enterprise value is 51.60 billion.
| Market Cap | 45.66B |
| Enterprise Value | 51.60B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Feb 9, 2026 |
Share Statistics
Aarti Drugs has 91.27 million shares outstanding. The number of shares has increased by 4.94% in one year.
| Current Share Class | 91.27M |
| Shares Outstanding | 91.27M |
| Shares Change (YoY) | +4.94% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 47.31% |
| Owned by Institutions (%) | 17.95% |
| Float | 35.37M |
Valuation Ratios
The trailing PE ratio is 19.96 and the forward PE ratio is 20.19.
| PE Ratio | 19.96 |
| Forward PE | 20.19 |
| PS Ratio | 1.60 |
| PB Ratio | 2.72 |
| P/TBV Ratio | 2.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 27.36 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 22.55 |
| EV / Sales | 1.81 |
| EV / EBITDA | 13.45 |
| EV / EBIT | 16.44 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.59 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.62 |
| Debt / FCF | n/a |
| Interest Coverage | 8.65 |
Financial Efficiency
Return on equity (ROE) is 14.52% and return on invested capital (ROIC) is 11.80%.
| Return on Equity (ROE) | 14.52% |
| Return on Assets (ROA) | 6.93% |
| Return on Invested Capital (ROIC) | 11.80% |
| Return on Capital Employed (ROCE) | 15.62% |
| Weighted Average Cost of Capital (WACC) | 5.57% |
| Revenue Per Employee | 21.04M |
| Profits Per Employee | 1.69M |
| Employee Count | 1,355 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.33 |
Taxes
In the past 12 months, Aarti Drugs has paid 491.94 million in taxes.
| Income Tax | 491.94M |
| Effective Tax Rate | 17.70% |
Stock Price Statistics
The stock price has increased by +1.86% in the last 52 weeks. The beta is 0.26, so Aarti Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +1.86% |
| 50-Day Moving Average | 424.72 |
| 200-Day Moving Average | 391.49 |
| Relative Strength Index (RSI) | 71.51 |
| Average Volume (20 Days) | 96,691 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aarti Drugs had revenue of INR 28.51 billion and earned 2.29 billion in profits. Earnings per share was 25.06.
| Revenue | 28.51B |
| Gross Profit | 10.63B |
| Operating Income | 3.14B |
| Pretax Income | 2.78B |
| Net Income | 2.29B |
| EBITDA | 3.82B |
| EBIT | 3.14B |
| Earnings Per Share (EPS) | 25.06 |
Balance Sheet
The company has 257.60 million in cash and 6.20 billion in debt, with a net cash position of -5.94 billion or -65.07 per share.
| Cash & Cash Equivalents | 257.60M |
| Total Debt | 6.20B |
| Net Cash | -5.94B |
| Net Cash Per Share | -65.07 |
| Equity (Book Value) | 16.82B |
| Book Value Per Share | 184.24 |
| Working Capital | 6.14B |
Cash Flow
In the last 12 months, operating cash flow was 1.67 billion and capital expenditures -1.69 billion, giving a free cash flow of -23.33 million.
| Operating Cash Flow | 1.67B |
| Capital Expenditures | -1.69B |
| Depreciation & Amortization | 685.65M |
| Net Borrowing | 575.40M |
| Free Cash Flow | -23.33M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 37.28%, with operating and profit margins of 11.01% and 8.03%.
| Gross Margin | 37.28% |
| Operating Margin | 11.01% |
| Pretax Margin | 9.75% |
| Profit Margin | 8.03% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 11.01% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.40%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.40% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.94% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.94% |
| Shareholder Yield | -4.54% |
| Earnings Yield | 5.01% |
| FCF Yield | -0.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on September 30, 2020. It was a forward split with a ratio of 4.
| Last Split Date | Sep 30, 2020 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |